Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Liangge San is a modified Traditional Chinese Medicine (TCM) formula based on the classic Liangge San (Cool the Diaphragm Powder). It is being developed and evaluated by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine as an adjunctive treatment for sepsis, specifically for patients exhibiting the exuberant heat toxin pattern. The formula is designed to clear heat, detoxify, and purge fire, thereby modulating the systemic inflammatory response and reducing organ damage. In clinical studies, it is administered alongside standard sepsis therapy to assess its impact on 28-day mortality, Sequential Organ Failure Assessment (SOFA) scores, and inflammatory biomarkers such as C-reactive protein and procalcitonin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiawei Liangge San.